BioSpace News Archive

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its first-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, May 12, 2021.

Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, reported that on May 3, 2021, the Company granted non-qualified stock options to purchase an aggregate of 51,200 shares of the Company’s common stock to six new employees.

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in-vitro diagnostics (IVD) companies, today announced financial results for the first quarter ended April 4, 2021.

Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, announced the results from its Annual General Meeting held today, May 5, 2021.

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the presentation of new data from a post hoc analysis of the Phase 1 ReCLAIM study evaluating elamipretide

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and financial results for the quarter ended March 31, 2021

Lumos Diagnostics announced today the expansion of its board with the appointment of three new independent directors to support the continued growth of the company’s rapid point-of-care diagnostic products and services business

For 2021, our focus is on three key areas: executing on the Monjuvi launch; rapidly advancing the tafasitamab backbone strategy through additional clinical studies; and expanding our pipeline,” said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys.

DBV Technologies, a clinical-stage biopharmaceutical company, announced the filing of its first Form 10-Q for the quarter ended March 31, 2021 with the U.S. Securities and Exchange Commission.

Cipher Pharmaceuticals Inc. (TSX:CPH) (“Cipher” or “the Company”) today announced it will release its Q1 2021 financial results after market close on Thursday, May 13, 2021. The company will hold a conference call on Friday, May 14, 2021 to discuss the results.